Lindbrook Capital’s MaxCyte MXCT Stock Holding History

Lindbrook Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-237	Closed	-$922	–	2867
2024 Q3	$922	Buy	237 +121	+104%	+$510	﹤0.01%	2518
2024 Q2	$455	Buy	+116	New	+$499	﹤0.01%	2635
2023 Q4	–	Sell	-423	Closed	-$1.32K	–	2774
2023 Q3	$1.32K	Buy	423 +98	+30%	+$394	﹤0.01%	2270
2023 Q2	$1.49K	Buy	325 +12	+4%	+$55	﹤0.01%	2264
2023 Q1	$1.55K	Buy	+313	New	+$1.54K	﹤0.01%	2343

Other funds holding MXCT

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lindbrook Capital's MXCT Position: Q4 2024 in Review

Lindbrook Capital sold out of MaxCyte (MXCT) in Q4 2024, closing a stake of 237 shares — an estimated $922 sold.

Lindbrook Capital first reported a position in MXCT in Q1 2023 and held it in 5 quarters. The position peaked at $1.55K in Q1 2023. 119 funds tracked by Wall St. Rank hold MXCT as of Q4 2024.

Lindbrook Capital reported no remaining MaxCyte position as of Q4 2024 after selling out during the quarter.
Lindbrook Capital sold 237 MaxCyte shares in Q4 2024, an estimated $922.
Lindbrook Capital first reported a position in MaxCyte in Q1 2023 and held it in 5 quarters.
Lindbrook Capital's MaxCyte position peaked at $1.55K in Q1 2023.
119 funds tracked by Wall St. Rank held MaxCyte as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.